Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults.

Author(s): Beeching NJ, Clarke PD, Kitchin NR, Pirmohamed J, Veitch K, Weber F

Affiliation(s): Clinical Research Group, Liverpool School of Tropical Medicine, UK.

Publication date & source: 2004-11-15, Vaccine., 23(1):29-35.

Publication type: Clinical Trial; Randomized Controlled Trial

A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine, Viatim, and the marketed Hepatyrix vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim compared with Hepatyrix. Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim vaccinees had more mild or moderate local reactions (82.7%) than Hepatyrix (53.1%, p < 0.001). In this direct comparison Viatim induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix.